BioLab Holdings Advances Venous Leg Ulcer Treatment with IRB Approval for Membrane Wrap Trial
核心洞察
BioLab Holdings (搜索) has received IRB approval for a multi-center randomized control trial to evaluate their Membrane Wrap (搜索) product's efficacy in treating venous leg ulcers (搜索) in elderly patients.
The Phoenix-based company will collaborate with 18 clinical sites to conduct the trial, with enrollment expected to begin following site agreement completion in the next 2-8 weeks.
The study marks BioLab's first randomized control trial for their human amniotic membrane-based wound care product, demonstrating their commitment to evidence-based treatment validation.
BioLab Holdings (搜索), Inc., a Phoenix-based medical manufacturer, has secured Institutional Review Board (IRB) approval for a landmark clinical trial evaluating their innovative wound care product, Membrane Wrap (搜索)™, in the treatment of venous leg ulcers (搜索).
The multi-center, prospective, randomized trial will assess the efficacy of the company's human amniotic membrane-based skin substitute specifically targeting elderly patients with venous leg ulcers (搜索). The study protocol was developed in partnership with MCRA (搜索), a Washington D.C.-based organization.
Dr. Marshall Medley, Chief Medical Officer at BioLab, expressed enthusiasm about the trial's potential impact: "We are very excited to be involved in this trial to ensure our Membrane Wrap (搜索)'s efficacy. This is the first of several randomized control trials we will be involved in, and we look forward to getting our products to even more patients in need of wound care."
Trial Implementation and Timeline
The study will span across 18 carefully vetted clinical sites. Site agreements are currently being distributed, with the enrollment phase expected to commence within the next two to eight weeks following agreement completion.
Product Innovation and Support Services
Membrane Wrap (搜索)™ is part of BioLab's comprehensive wound care portfolio, which includes variations such as Membrane Wrap Lite™, Tri-Membrane Wrap™, and Membrane Wrap - Hydro™. These products utilize human tissue allograft derived from amniotic membrane, serving as wound protectant coverings while maintaining the tissue's natural properties through minimal manipulation.
BioLab distinguishes itself in the wound care market through its holistic approach to provider support. The company offers comprehensive services including:
- Pre-application support with product protocols and timeline guidance
- Application training and product inservice education
- Benefits and insurance verification assistance
- Billing training and support
- Post-application support including proof-of-concept guidance
- Denied claims assistance and charity care services
This integrated approach ensures healthcare providers receive complete support throughout the wound care treatment process, from initial product application to follow-up care.